×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ENLV – enlivex therapeutics ltd. - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ENLV
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/24
08:09 am
enlv
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its price target raised by analysts at HC Wainwright from $6.00 to $7.00. They now have a "buy" rating on the stock.
Medium
Report
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its price target raised by analysts at HC Wainwright from $6.00 to $7.00. They now have a "buy" rating on the stock.
3/17
08:07 am
enlv
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis [Yahoo! Finance]
Medium
Report
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis [Yahoo! Finance]
3/17
08:00 am
enlv
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
Medium
Report
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
3/4
04:30 pm
enlv
Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis
Low
Report
Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis
3/3
10:47 am
enlv
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $13.00 price target on the stock.
Low
Report
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $13.00 price target on the stock.
3/3
08:22 am
enlv
Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis
High
Report
Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis
2/18
08:10 am
enlv
Enlivex Issues Urgent Statement on Fraudulent News Dissemination [Yahoo! Finance]
Low
Report
Enlivex Issues Urgent Statement on Fraudulent News Dissemination [Yahoo! Finance]
2/18
06:20 am
enlv
Enlivex Issues Urgent Statement on Fraudulent News Dissemination
Low
Report
Enlivex Issues Urgent Statement on Fraudulent News Dissemination
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/31
04:30 pm
enlv
Form 6-K Enlivex Therapeutics For: Mar 31
Low
Report
Form 6-K Enlivex Therapeutics For: Mar 31
3/17
08:02 am
enlv
Form 6-K Enlivex Therapeutics For: Mar 17
Medium
Report
Form 6-K Enlivex Therapeutics For: Mar 17
3/4
04:33 pm
enlv
Form 6-K Enlivex Therapeutics For: Mar 04
Neutral
Report
Form 6-K Enlivex Therapeutics For: Mar 04
3/3
08:23 am
enlv
Form 6-K Enlivex Therapeutics For: Mar 03
High
Report
Form 6-K Enlivex Therapeutics For: Mar 03
2/18
06:22 am
enlv
Form 6-K Enlivex Therapeutics For: Feb 18
Medium
Report
Form 6-K Enlivex Therapeutics For: Feb 18
2/14
05:43 pm
enlv
Form SCHEDULE 13G/A Enlivex Therapeutics Filed by: ARMISTICE CAPITAL, LLC
Neutral
Report
Form SCHEDULE 13G/A Enlivex Therapeutics Filed by: ARMISTICE CAPITAL, LLC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
7/16
Immunotherapy Company Enlivex Announces Dual Listing on the Tel-Aviv Stock Exchange
13.1%
3/13 Enlivex Therapeutics Ltd. (NASDAQ: ENLV) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $5.50 price target on the stock. 10.8%
11/14 Form 6-K Enlivex Therapeutics For: Nov 14 10.5%
6/24 Form EFFECT Enlivex Therapeutics 9.2%
3/20 Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock. 9.0%
9/23 First Data On Combination Of Enlivex’s Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Revealed At The Joint IIS-ISCR Special 2019 Conference 7.2%
11/20 Form 424B5 Enlivex Therapeutics 6.9%
3/9 Israel Patent Office Grants New Patent Covering Enlivex’s Allocetra Immunotherapy Treatment 5.6%
11/18 Enlivex Therapeutics Completes Recruitment In Phase Ib Trial Evaluating Safety And Efficacy Of Universal Off-The-Shelf Allocetra In Patients With Severe Sepsis 5.3%
7/10 Form 424B3 Enlivex Therapeutics 4.5%
3/13 Enlivex Therapeutics Ltd. (NASDAQ: ENLV) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $5.50 price target on the stock. 10.8%
11/14 Form 6-K Enlivex Therapeutics For: Nov 14 10.5%
6/24 Form EFFECT Enlivex Therapeutics 9.2%
3/20 Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock. 9.0%
9/23 First Data On Combination Of Enlivex’s Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Revealed At The Joint IIS-ISCR Special 2019 Conference 7.2%
11/20 Form 424B5 Enlivex Therapeutics 6.9%
3/9 Israel Patent Office Grants New Patent Covering Enlivex’s Allocetra Immunotherapy Treatment 5.6%
11/18 Enlivex Therapeutics Completes Recruitment In Phase Ib Trial Evaluating Safety And Efficacy Of Universal Off-The-Shelf Allocetra In Patients With Severe Sepsis 5.3%
7/10 Form 424B3 Enlivex Therapeutics 4.5%
TOP News Decliners
3/18
Form 6-K Enlivex Therapeutics For: Mar 18
-29.3%
2/24 Enlivex's stock rockets after plans to boost in capacity for treatment of COVID-19-like symptoms [MarketWatch] -26.0%
10/7 Data On Combination Of Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Selected For Presentation At The European Molecular Biology Organization’s 2019 Cell Death in Immunity and Inflammation Workshop -19.3%
10/8 European Patent Office Grants New Patent Covering Enlivex’s Allocetra™ Immunotherapy Treatment -12.0%
3/5 Enlivex Therapeutics Closes $16.75 Million Registered Direct Offering -9.7%
3/26 Greenberg Traurig Assists Enlivex Therapeutics with $24.75 Million in Financing -9.6%
10/10 Preclinical Data Indicating Allocetra-OTS As Potential Therapy For Prevention Of Organ Failure And Mortality Associated with Severe Sepsis Selected For Presentation At The XVIIIth Congress Of the European and Int'l Shock Societies -9.4%
6/6 Enlivex Therapeutics Provides Clinical Update on Positive Safety Profile of Its Off-The-Shelf Cell Therapy Product in First Three Severe Sepsis Patients -8.3%
1/23 Form 20-F/A Enlivex Therapeutics For: Dec 31 -8.2%
3/3 Form 424B5 Enlivex Therapeutics -6.5%
2/24 Enlivex's stock rockets after plans to boost in capacity for treatment of COVID-19-like symptoms [MarketWatch] -26.0%
10/7 Data On Combination Of Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Selected For Presentation At The European Molecular Biology Organization’s 2019 Cell Death in Immunity and Inflammation Workshop -19.3%
10/8 European Patent Office Grants New Patent Covering Enlivex’s Allocetra™ Immunotherapy Treatment -12.0%
3/5 Enlivex Therapeutics Closes $16.75 Million Registered Direct Offering -9.7%
3/26 Greenberg Traurig Assists Enlivex Therapeutics with $24.75 Million in Financing -9.6%
10/10 Preclinical Data Indicating Allocetra-OTS As Potential Therapy For Prevention Of Organ Failure And Mortality Associated with Severe Sepsis Selected For Presentation At The XVIIIth Congress Of the European and Int'l Shock Societies -9.4%
6/6 Enlivex Therapeutics Provides Clinical Update on Positive Safety Profile of Its Off-The-Shelf Cell Therapy Product in First Three Severe Sepsis Patients -8.3%
1/23 Form 20-F/A Enlivex Therapeutics For: Dec 31 -8.2%
3/3 Form 424B5 Enlivex Therapeutics -6.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: